Women's health innovations face nine structural barriers that prevent them from securing reimbursement, stalling promising treatments not because the science is lacking but because a clear route to payment doesn't exist. The Coverage and Reimbursement Roadmap for Women's Health Innovation, published by the Milken Institute Women's Health Network, maps out the fundamental coverage challenges shaping innovation in the United States for conditions that affect women exclusively, differentially, or disproportionately. The roadmap emerged from a workshop that brought together clinicians, payers, regulators, and innovators to chart a path through a system built on inadequate research, insufficient billing codes, and payers slow to recognize women's specific health needs.
The report identifies those nine structural barriers standing between women's health innovations and reimbursement, though it doesn't enumerate each one individually in the summary material provided. It contrasts two fundamental pathways for innovators: self-pay models and payer coverage routes, emphasizing that the decision between them should be made early in the development process. The guide breaks down three primary coverage pathways—self-pay, commercial payer coverage, and public programs—and addresses the complexities within each, from Medicaid's state-by-state variation to Medicare's four distinct parts.
The Milken Institute Women's Health Network convened the Coverage and Reimbursement Working Group specifically to examine these challenges and create practical guidance for innovators navigating the reimbursement landscape. According to the report, women's health has long been underserved by a coverage system built around inadequate research and insufficient billing codes. The roadmap provides step-by-step guidance on key considerations and optimal timing for each coverage pathway, from initial concept through to patient access.
The barriers exist because the healthcare payment system wasn't designed with women's specific health conditions in mind, the report explains. Inadequate historical research has meant fewer recognized medical codes for billing, which in turn makes it harder for payers to approve coverage for new treatments targeting conditions that affect women uniquely or in different ways than men. This creates a circular problem: without codes, there's no payment pathway; without a payment pathway, innovators struggle to bring solutions to market; and without market adoption, the research gaps persist. The roadmap aims to break this cycle by giving innovators clear guidance on how to navigate existing systems while those systems slowly evolve to better serve women's health needs.
For women's health innovators, the choice between pursuing a self-pay model or seeking payer coverage represents a critical early decision that shapes the entire development trajectory. The roadmap offers concrete direction on timing—when to engage with commercial payers versus when to target public programs, and how to sequence those approaches for maximum success. By laying out the reimbursement pathway from concept to patient access with specificity about state-level Medicaid differences and Medicare's segmented structure, the guide provides the clarity that innovators have lacked, potentially unlocking treatments that have stalled despite sound science.